Boeri M, Saure D, Schuster C, Hill J, Guerreiro M, Hauber B. Do clinical and demographic characteristics affect patient preference heterogeneity for psoriasis treatments? Results from a discrete-choice experiment in a multicountry study. Poster presented at the ISPOR 2019 European Conference; November 4, 2019. Copenhagen, Denmark. [abstract] Value Health. 2019 Dec; 22(S3).

OBJECTIVES: Several therapeutic options exist for the treatment of plaque psoriasis and different patients may prefer different treatments. This study aimed to elicit patients’ preferences for psoriasis treatments and to test whether patients with different characteristics have systematically different preferences.

METHODS: A discrete-choice experiment (DCE) was employed to elicit preferences of patients with plaque psoriasis in multiple countries. The survey instrument included a series of choice questions between three hypothetical treatments, each characterized by varying levels of six attributes: mode and frequency of application, time to reach clinically meaningful results, reduction in psoriasis lesions, reduction in itching, risk of moderate-to-severe side effects, and frequency and duration of the appearance of side effect. Random parameters logit was used to model the data. Results were compared across multiple subgroups defined by country, comorbidities, location of psoriasis plaques, body surface area, age, and marital status using a Wald test for systematic differences in preferences between subgroup.

The survey was completed by 1,123 respondents in Canada, France, Spain, Italy, and the United Kingdom (UK). On average, respondents preferred weekly tablets to other modes of administration. Preference for attributes with naturally ordered levels were ordered as expected (e.g. higher efficacy and lower side effects were preferred). In addition, we found significant differences between male and female (P<0.001), respondents from Italy or France compared to the UK (P<0.001), respondents with body surface area between 3% and 10% compared to less than 3% (P=0.004), as well as respondents with concomitant genital or nail psoriasis or psoriatic arthritis (P<0.001). There was no evidence of systematic differences between respondents with and without psoriasis on the face or in other subgroups considered.

CONCLUSIONS: We identified systematic differences in preferences across multiple subgroups indicating that determining the appropriate psoriasis treatment may be informed by patient characteristics and their preferences.

Share on: